Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716962 | 0.83 | POLA1 (0.52) | POLA1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6684490 | 0.83 | ALDH1A1 (0.41) | POLA1ALDH1A1NPC1RAB9ATSHR | |
| SCHEMBL6288507 | 0.77 | KCNH2 (0.53) | POLA1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6670929 | 0.77 | POLA1 (0.50) | POLA1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6682832 | 0.77 | MMP3 (0.42) | ALDH1A1TSHRMAPTSMN1; SMN2 | |
| SCHEMBL6201283 | 0.76 | KCNH2 (0.54) | POLA1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6668933 | 0.76 | KCNH2 (0.52) | POLA1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6286783 | 0.75 | KCNH2 (0.59) | POLA1KCNH2ALDH1A1 | |
| SCHEMBL6665763 | 0.74 | KCNH2 (0.54) | POLA1KCNH2ALDH1A1NPC1RAB9A | |
| SCHEMBL6280321 | 0.74 | KCNH2 (0.52) | POLA1KCNH2ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | claimed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | claimed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | claimed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-09-09 | — | — | US | disclosed |
| US-6730682-B2 | HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2004-05-04 | — | — | US | disclosed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-1363907-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2002004443-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176366-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, NR1H3, NR1H2 | POLA1 2447/4885KCNH2 4095/4885ALDH1A1 1190/4885 |
| US-20040180910-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885KCNH2 919/4885ALDH1A1 779/4885 |
| US-20020019397-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | POLA1 267/4885KCNH2 919/4885ALDH1A1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.